May 18, 2022
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
May 17, 2022
Appili Therapeutics Announces Overnight Marketed Equity Offering
April 27, 2022
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2022
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
March 29, 2022
Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings
March 9, 2022
Appili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor Forum
February 28, 2022
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
February 14, 2022
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
February 8, 2022
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals